LUCY
BEARISH
$1.1
Live
Lucyd, Inc · NASDAQ
Target $3.0
(+172.7%)
$0.95
52W Range
$4.97
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$6.93M
P/E
N/A
ROE
-83.6%
Profit margin
-285.2%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
LUCY exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While the company shows strong top-line revenue growth of 39% and a consistent track record of beating earnings estimates, these are overshadowed by a catastrophic profit margin of -285.20% and a 5-year price collapse of 99.1%. The high current ratio (9.03) suggests a temporary liquidity cushion, but the overall trajectory remains highly speculative and fundamentally unstable.
Key Strengths
Strong YoY revenue growth of 39.00%
Consistent earnings beats (4/4 in the last 4 quarters)
High liquidity with a current ratio of 9.03
Trading below book value (Price/Book: 0.67)
Improving EPS trend with recent Q/Q growth of 26.3%
Key Risks
Extreme operational inefficiency (Profit Margin: -285.20%)
Critical fundamental health (Piotroski F-Score: 1/9)
Severe long-term capital erosion (-99.1% 5-year change)
Micro-cap volatility and low market capitalization ($0.01B)
Lack of positive earnings or a path to immediate profitability
AI Fair Value Estimate
Based on comprehensive analysis
$1.45
+31.8% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
40
55
5
10
0
AI Verdict
High-Risk Speculative
Key drivers: Critical Piotroski F-Score, Extreme negative margins, Strong revenue growth, Catastrophic historical price performance
Confidence
90%
Value
40/100
Ref P/E (N/A), P/B (0.67), Graham Number (None)
Positives
- P/B ratio of 0.67 suggests the stock is undervalued relative to assets
Watchpoints
- P/S ratio of 2.60 is high for a company with such deep losses
- No Graham Number available due to lack of earnings
Future
55/100
Ref Growth rates and EPS surprises
Positives
- 39% YoY revenue growth
- Positive EPS surprise trend
Watchpoints
- High burn rate relative to revenue
- Unproven ability to scale to profitability
Past
5/100
Ref Historical price trends
Positives
No standout positives identified.
Watchpoints
- 5-year return of -99.1%
- 1-year return of -48.1%
Health
10/100
Ref Piotroski F-Score, ROE
Positives
- Strong current ratio (9.03)
Watchpoints
- Piotroski F-Score of 1/9 indicates severe weakness
- ROE of -83.60%
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.1
Analyst Target
$3.0
Upside/Downside
+172.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LUCY and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LUCY
Lucyd, Inc
Primary
|
-99.1% | -98.6% | -48.1% | -41.2% | -1.8% | +1.9% |
|
ITOC
iTonic Holdings Ltd.
Peer
|
-92.6% | -92.6% | -90.8% | -60.0% | -17.4% | -8.2% |
|
MGRX
Mangoceuticals, Inc.
Peer
|
-99.3% | -97.5% | -78.4% | -84.5% | +2.4% | +2.4% |
|
BRTX
BioRestorative Therapies, Inc.
Peer
|
-99.5% | -93.0% | -85.2% | -84.5% | +8.1% | -7.9% |
|
BMRA
Biomerica, Inc.
Peer
|
-95.7% | -88.5% | -46.5% | -34.3% | -3.0% | 0.0% |
LUC
Lucyd, Inc
Primary
5Y
-99.1%
3Y
-98.6%
1Y
-48.1%
6M
-41.2%
1M
-1.8%
1W
+1.9%
ITO
iTonic Holdings Ltd.
Peer
5Y
-92.6%
3Y
-92.6%
1Y
-90.8%
6M
-60.0%
1M
-17.4%
1W
-8.2%
MGR
Mangoceuticals, Inc.
Peer
5Y
-99.3%
3Y
-97.5%
1Y
-78.4%
6M
-84.5%
1M
+2.4%
1W
+2.4%
BRT
BioRestorative Therapies, Inc.
Peer
5Y
-99.5%
3Y
-93.0%
1Y
-85.2%
6M
-84.5%
1M
+8.1%
1W
-7.9%
BMR
Biomerica, Inc.
Peer
5Y
-95.7%
3Y
-88.5%
1Y
-46.5%
6M
-34.3%
1M
-3.0%
1W
0.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-2.44
PEG Ratio
N/A
P/B Ratio
0.67
P/S Ratio
2.6
EV/Revenue
0.16
EV/EBITDA
-0.05
Market Cap
$6.93M
Profitability
Profit margins and return metrics
Profit Margin
-285.2%
Operating Margin
-260.39%
Gross Margin
21.32%
ROE
-83.6%
ROA
-53.15%
Growth
Revenue and earnings growth rates
Revenue Growth
+39.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+38.96%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
9.03
Strong
Quick Ratio
6.68
Excellent
Cash/Share
$1.03
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
12.0%
Op. Margin
-260.4%
Net Margin
-194.8%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.12x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
113%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-25
$-0.28
+34.9% surprise
2025-11-13
$-0.38
+22.4% surprise
2025-08-14
$-0.66
+14.3% surprise
2025-05-13
$-0.72
+1.4% surprise
Healthcare Sector Comparison
Comparing LUCY against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-83.6%
This Stock
vs
-86.0%
Sector Avg
-2.8%
(Below Avg)
Profit Margin
-285.2%
This Stock
vs
-11.76%
Sector Avg
+2325.4%
(Superior)
Revenue Growth
39.0%
This Stock
vs
90.15%
Sector Avg
-56.7%
(Slower)
Current Ratio
9.03
This Stock
vs
3.67
Sector Avg
+146.2%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LUCY
Lucyd, Inc
|
BEARISH | $6.93M | - | -83.6% | -285.2% | $1.1 | |
|
ITOC
iTonic Holdings Ltd.
|
BEARISH | $6.92M | - | -71.2% | -% | $0.28 | Compare |
|
MGRX
Mangoceuticals, Inc.
|
BEARISH | $6.67M | - | -141.7% | -% | $0.39 | Compare |
|
BRTX
BioRestorative Therapies, Inc.
|
BEARISH | $6.39M | - | -320.5% | -% | $0.25 | Compare |
|
BMRA
Biomerica, Inc.
|
BEARISH | $7.76M | - | -84.3% | -90.3% | $2.57 | Compare |
LUCY
Lucyd, Inc
BEARISH
Mkt Cap
$7M
P/E
-
ROE
-83.6%
Price
$1.1
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-21 | GROSS HARRISON R | Chief Executive Officer | Purchase | 1,500 | $1,980 |
| 2026-01-13 | GAYLE OSWALD | Chief Financial Officer | Purchase | 1,000 | $1,669 |
| 2026-01-08 | DABROWSKI KONRAD | Officer | Purchase | 1,300 | $2,054 |
| 2026-01-08 | GROSS HARRISON R | Chief Executive Officer | Purchase | 1,500 | $2,400 |
| 2025-12-18 | GALKIN VLADIMIR | Beneficial Owner of more than 10% of a Class of Security | Purchase | 12,966 | $17,893 |
| 2025-12-11 | GALKIN VLADIMIR | Beneficial Owner of more than 10% of a Class of Security | Purchase | 58,723 | $88,255 |
GROSS HARRISON R
Chief Executive Officer
2026-01-21
1,500 shares
·
$1,980
GAYLE OSWALD
Chief Financial Officer
2026-01-13
1,000 shares
·
$1,669
DABROWSKI KONRAD
Officer
2026-01-08
1,300 shares
·
$2,054
GROSS HARRISON R
Chief Executive Officer
2026-01-08
1,500 shares
·
$2,400
GALKIN VLADIMIR
Beneficial Owner of more than 10% of a Class of Security
2025-12-18
12,966 shares
·
$17,893
GALKIN VLADIMIR
Beneficial Owner of more than 10% of a Class of Security
2025-12-11
58,723 shares
·
$88,255
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning LUCY from our newsroom.
Newest → oldest
No matching news yet.